MaxCyte MXCT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.75M+50.5% | -$9.6M+22.7% | -$12.42M-0.5% | -$12.36M-20.4% | -$10.26M+3.2% | ||
| $1.05M-2.3% | $1.07M0.0% | $1.07M-2.5% | $1.1M+0.4% | $1.1M+3.7% | ||
| $1.14M+61.6% | $706K-63.9% | $1.95M-44.4% | $3.51M+15.6% | $3.04M-3.0% | ||
| —— | $888.5K0.0% | $888.5K0.0% | $888.5K0.0% | $888.5K— | ||
| —— | -$155K-716% | -$19K+71.2% | -$66K-40.4% | -$47K+88.2% | ||
| $743K+115% | -$4.8M-287% | $2.57M+981% | $238K-71.6% | $839K— | ||
| $380K— | —— | —— | -$223K+58.0% | -$531K-0.8% | ||
| -$3.64M-850% | -$383K— | —— | —— | -$5.59M-1,107% | ||
| $127K— | —— | —— | $886K+249% | $254K-47.2% | ||
| -$1K— | —— | -$21K+4.5% | -$22K-450% | -$4K-33.3% | ||
| -$327K+79.5% | -$1.6M— | —— | -$1.51M-13.5% | -$1.33M— | ||
| $221K+2.8% | $215K+2.9% | $209K+6.1% | $197K+8.8% | $181K+48.4% | ||
| -$456K-109% | -$218K+37.0% | -$346K-9.8% | -$315K-13.3% | -$278K+2.5% | ||
| -$8.17M-204% | -$2.69M+63.9% | -$7.46M+24.3% | -$9.85M+31.6% | -$14.41M-84.3% | ||
| $72K-68.8% | $231K-23.0% | $300K-48.6% | $584K-10.6% | $653K+344% | ||
| —— | —— | —— | —— | $1.77M— | ||
| $25.12M-11.1% | $28.26M-18.1% | $34.51M+19.5% | $28.88M-16.6% | $34.65M+6.5% | ||
| $28M-26.6% | $38.16M-4.6% | $40M+29.0% | $31M-33.5% | $46.6M+50.3% | ||
| $150K— | —— | —— | —— | —— | ||
| $2.66M-72.6% | $9.68M+86.4% | $5.19M+238% | $1.54M-83.9% | $9.53M— | ||
| $5K-66.7% | $15K+7.1% | $14K-30.0% | $20K-94.8% | $383K+75.7% | ||
| $5K-95.2% | $105K+650% | $14K-90.9% | $154K-59.8% | $383K-7.0% | ||
| -$5.51M— | —— | -$2.25M+72.4% | -$8.16M-81.4% | -$4.5M+50.4% | ||
| $437K+2.3% | $427K-26.9% | $584K-22.2% | $751K-15.0% | $884K-25.7% | ||
| -$327K+79.5% | -$1.6M— | —— | -$1.51M-13.5% | -$1.33M— | ||
| -$456K-109% | -$218K+37.0% | -$346K-9.8% | -$315K-13.3% | -$278K+2.5% | ||
| -$69K-105% | $1.28M+4,297% | $29K+104% | -$708K-989% | -$65K+87.5% | ||
| $197K+30.5% | $151K-58.1% | $360K+260% | $100K+53.8% | $65K-93.1% | ||
| $14K+7.7% | $13K-13.3% | $15K— | —— | —— | ||
| $221K+2.8% | $215K+2.9% | $209K+6.1% | $197K+8.8% | $181K+48.4% | ||
| $150K— | —— | —— | —— | —— | ||
| $28M-26.6% | $38.16M-4.6% | $40M+29.0% | $31M-33.5% | $46.6M+50.3% | ||
| $24K+500% | $4K— | —— | —— | —— | ||
| -$456K-109% | -$218K+37.0% | -$346K-9.8% | -$315K-13.3% | -$278K+2.5% | ||
| —— | —— | —— | —— | $956K— | ||
| -$8.24M-182% | -$2.92M+62.4% | -$7.76M+25.7% | -$10.44M+30.7% | -$15.06M-89.1% | ||
| -$8.24M-182% | -$2.92M+62.4% | -$7.76M+25.7% | -$10.44M+30.7% | -$15.06M-89.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MaxCyte generate?
- MaxCyte (MXCT) generated -$28.2M in operating cash flow over the trailing twelve months.
- What is MaxCyte's free cash flow?
- After $1.2M of capital expenditures, MaxCyte's free cash flow was -$29.4M over the trailing twelve months, up 10.9% year over year.
- Where does MaxCyte's cash flow data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
